Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
176.98+3.04 (+1.75%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close173.94
Open174.85
Bid176.70 x 1000
Ask176.61 x 1200
Day's Range174.07 - 177.15
52 Week Range155.72 - 186.69
Volume7,522,122
Avg. Volume7,704,381
Market Cap465.918B
Beta (5Y Monthly)0.72
PE Ratio (TTM)26.45
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield4.52 (2.56%)
Ex-Dividend DateMay 23, 2022
1y Target EstN/A
  • Investor's Business Daily

    JNJ Stock Still Outperforms S&P 500; How To Enhance Gains With A Covered Call

    Selling the call option generates an income of 1.7% in just under one month, equaling around 26.7% annualized.

  • Benzinga

    US Raises Objection To Johnson & Johnson's High Cost Lawyer For Talc Bankruptcy Case: Reuters

    Johnson & Johnson (NYSE: JNJ) is ready to cough up an hourly rate of $2,465 in a bid to add Hogan Lovells partner Neal Katyal to its legal team for the talc liability case. The controversial bankruptcy case tries to free JNJ from potentially billions in liabilities over its talc products claiming to cause cancer. The U.S. government is objecting, citing his hourly rate as a possible new legal industry high. Related: Johnson & Johnson's Baby Talc Litigation, Faces Fresh Claims It Hid Evidence: Bl

  • Motley Fool

    2 Top Biotech Stocks to Buy in May

    Pharma stocks Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) have gained 23% and 5%, respectively, year to date. Merck had five blockbuster products in 2021, including the top-selling cancer drug in the world, Keytruda.

Advertisement
Advertisement